These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 10558040)
1. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Ramsey SD; Newton K; Blough D; McCulloch DK; Sandhu N; Wagner EH Pharmacoeconomics; 1999 Sep; 16(3):285-95. PubMed ID: 10558040 [TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
3. Excess costs of medical care for patients with diabetes in a managed care population. Selby JV; Ray GT; Zhang D; Colby CJ Diabetes Care; 1997 Sep; 20(9):1396-402. PubMed ID: 9283786 [TBL] [Abstract][Full Text] [Related]
4. [Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study]. Köster I; Hauner H; von Ferber L Dtsch Med Wochenschr; 2006 Apr; 131(15):804-10. PubMed ID: 16607599 [TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808 [TBL] [Abstract][Full Text] [Related]
6. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912 [TBL] [Abstract][Full Text] [Related]
7. Economic costs of diabetes in the U.S. In 2007. American Diabetes Association Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683 [TBL] [Abstract][Full Text] [Related]
8. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Ramsey SD; Newton K; Blough D; McCulloch DK; Sandhu N; Reiber GE; Wagner EH Diabetes Care; 1999 Mar; 22(3):382-7. PubMed ID: 10097914 [TBL] [Abstract][Full Text] [Related]
9. Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from young and middle-aged incidence cohorts in Sweden. Jonsson PM; Marké LA; Nyström L; Wall S; Ostman J Diabetes Res Clin Pract; 2000 Sep; 50(1):35-47. PubMed ID: 10936667 [TBL] [Abstract][Full Text] [Related]
10. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Ritzwoller DP; Ellis JL; Korner EJ; Hartsfield CL; Sadosky A Curr Med Res Opin; 2009 Jun; 25(6):1319-28. PubMed ID: 19419344 [TBL] [Abstract][Full Text] [Related]
11. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. von Ferber L; Köster I; Hauner H Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):97-104. PubMed ID: 17318768 [TBL] [Abstract][Full Text] [Related]
12. A computer simulation model of diabetes progression, quality of life, and cost. Zhou H; Isaman DJ; Messinger S; Brown MB; Klein R; Brandle M; Herman WH Diabetes Care; 2005 Dec; 28(12):2856-63. PubMed ID: 16306545 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965 [TBL] [Abstract][Full Text] [Related]
14. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083 [TBL] [Abstract][Full Text] [Related]
15. The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study. Köster I; von Ferber L; Ihle P; Schubert I; Hauner H Diabetologia; 2006 Jul; 49(7):1498-504. PubMed ID: 16752168 [TBL] [Abstract][Full Text] [Related]
16. The cost of diabetes in the presence of comorbid conditions. Garis RI; Shara MA; Farmer KC; Horrell JF; Arora M Manag Care Interface; 2002 Apr; 15(4):48-53, 55. PubMed ID: 11979705 [TBL] [Abstract][Full Text] [Related]
17. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). Martin S; Schramm W; Schneider B; Neeser K; Weber C; Lodwig V; Heinemann L; Scherbaum WA; Kolb H Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):495-501. PubMed ID: 17853332 [TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Maetzel A; Ruof J; Covington M; Wolf A Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990 [TBL] [Abstract][Full Text] [Related]
19. The cost of diabetes in Latin America and the Caribbean. Barceló A; Aedo C; Rajpathak S; Robles S Bull World Health Organ; 2003; 81(1):19-27. PubMed ID: 12640472 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Almbrand B; Johannesson M; Sjöstrand B; Malmberg K; Rydén L Eur Heart J; 2000 May; 21(9):733-9. PubMed ID: 10739728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]